Association of Nonalcoholic Hepatic Fibrosis with Body Composition in Female and Male Psoriasis Patients.
NAFLD
body composition
body weight
hepatic fibrosis
psoriasis
Journal
Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444
Informations de publication
Date de publication:
29 Jul 2021
29 Jul 2021
Historique:
received:
04
06
2021
revised:
13
07
2021
accepted:
20
07
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
28
8
2021
Statut:
epublish
Résumé
Psoriasis has been associated with increased frequency of hepatic diseases. Psoriasis severity, obesity, insulin resistance, aspartate aminotransferase level, platelet count, and alcohol use are significant predictors for advanced fibrosis in psoriasis patients. Although psoriasis patients also present body composition changes (e.g., higher overall body fat, visceral fat and sarcopenia), and these have recently been reported as risk factors for hepatic fibrosis, to date, body composition has not been prospectively investigated in psoriasis in the context of liver fibrosis. In this study anthropometric assessment (body weight and body mass index (BMI)), body composition analysis (body fat%, visceral fat scores and muscle mass%), and liver stiffness measurements (using transient elastography [TE]) were done in 52 psoriasis patients undergoing methotrexate therapy. Fourteen patients (26.9%) had advanced (F3-F4) liver fibrosis. There was no correlation between the patients' liver stiffness values and the cumulative MTX doses. On the other hand, patients with higher BMI values, total body fat% and visceral fat scores were significantly more likely to present with higher hepatic stiffness values. BMI was a significant predictor of hepatic fibrosis in both genders. In males, body fat% (R = 0.578,
Identifiants
pubmed: 34440507
pii: life11080763
doi: 10.3390/life11080763
pmc: PMC8398768
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Dermatology. 2020;236(4):369-374
pubmed: 32403113
Psoriasis (Auckl). 2018 May 09;8:21-29
pubmed: 29785393
Am J Med. 2009 Dec;122(12):1150.e1-9
pubmed: 19958894
Acta Derm Venereol. 2017 Aug 31;97(8):952-954
pubmed: 28422266
J Int Med Res. 2020 Oct;48(10):300060520964024
pubmed: 33121308
Arch Dermatol Res. 2017 Jul;309(5):403-408
pubmed: 28303329
Prz Gastroenterol. 2016;11(4):263-269
pubmed: 28053681
Arch Toxicol. 2018 May;92(5):1831-1845
pubmed: 29594327
JAMA Dermatol. 2019 Sep 1;155(9):1028-1032
pubmed: 31166567
Clin Res Hepatol Gastroenterol. 2020 Jan-Jun;44S:100003
pubmed: 33602481
Int J Mol Sci. 2016 Feb 05;17(2):217
pubmed: 26861300
Rev Endocr Metab Disord. 2017 Jun;18(2):195-205
pubmed: 28176237
Int J Dermatol. 2018 Oct;57(10):1165-1172
pubmed: 29729012
PLoS One. 2020 Aug 13;15(8):e0237598
pubmed: 32790787
Indian J Dermatol Venereol Leprol. 2020 Sep-Oct;86(5):508-514
pubmed: 32525101
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20
pubmed: 28930295
Br J Dermatol. 2014 Aug;171(2):436-8
pubmed: 24641699
JAMA Dermatol. 2017 Oct 1;153(10):977-982
pubmed: 28832872
Indian J Dermatol Venereol Leprol. 2020 Nov-Dec;86(6):649-655
pubmed: 32643632
Am J Clin Nutr. 2000 Sep;72(3):694-701
pubmed: 10966886
Psoriasis (Auckl). 2019 Aug 21;9:75-79
pubmed: 31687362
Indian Dermatol Online J. 2020 May 10;11(3):387-390
pubmed: 32695699
Int J Environ Res Public Health. 2016 Jul 22;13(5):
pubmed: 27455297
Semin Cutan Med Surg. 2015 Mar;34(2 Suppl):S30-3
pubmed: 26624961
J Dermatolog Treat. 2017 Jun;28(4):299-303
pubmed: 27786575
Crit Rev Food Sci Nutr. 2020 Sep 24;:1-17
pubmed: 32969257
Gastroenterology. 2019 May;156(6):1717-1730
pubmed: 30689971
Aliment Pharmacol Ther. 2015 Feb;41(3):293-300
pubmed: 25521607